Patient death reported in Bristol Myers Squibb autoimmune CAR-T trial

• Bristol Myers Squibb reported a patient death in a Phase 1 trial for an autoimmune CAR-T therapy.
• The therapy was being tested for its effectiveness in treating multiple sclerosis.
• The patient experienced unresolved motor symptoms after receiving the therapy.
• The incident adds to safety concerns in the field of CAR-T research.
• Bristol Myers Squibb disclosed the death in an early-stage cell therapy study.